• November 3, 2022

    Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

    – Clinical stage biopharmaceutical company completes upsized, [...]

  • June 24, 2022

    Outstanding First Half for Paragon and its Portfolio Companies

    Paragon and its portfolio companies continue to [...]

  • May 25, 2022

    Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline

    – Funding expected to provide sufficient capital [...]

  • April 5, 2022

    Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies

    Expansion builds on initial strategic collaboration and [...]

  • March 1, 2022

    Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation

    License agreement secures potential research of ecopipam for [...]